Tokyo Tape
Sign in
← PHC Holdings

Quarterly report · Q2

6523.TEDINET S100S7VD
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥166.8bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥85.5bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥356.4bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥170.6bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥89.1bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥4.2bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥2.5bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥10.5bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥8.5bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax−¥3.0bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥557m2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥179m2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥3.4bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥9.7bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)−¥2.5bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥743m2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥3.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.2bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥8.3bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥2.4bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥733m2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥8.5bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥570.4bnat 2023-09-30Cons.Assets IFRS
Total assets¥561.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥596.3bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥423.4bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥422.7bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥147.0bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥138.8bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥149.3bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥136.1bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥147.4bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥138.0bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥148.3bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥61.4bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥60.9bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥73.7bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥95.2bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥22.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥21.4bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥5.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥2.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥17.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥8.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥23.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥40.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥20.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-19.552023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥5.912023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥-25.842022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥9.612022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥66.62022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-19.552023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥5.882023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥-25.842022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥9.522022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥65.982022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio25.8%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.6%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.9%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥1.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥4.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2023-04-01 → 2023-09-30¥52.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2023-04-01 → 2023-09-30¥52.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2023-04-01 → 2023-09-30¥4.7bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2023-04-01 → 2023-09-30¥51.1bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2023-04-01 → 2023-09-30¥51.1bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2023-04-01 → 2023-09-30¥2.5bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2023-04-01 → 2023-09-30¥61.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2023-04-01 → 2023-09-30¥61.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.7bn
—segment totalrevenue2023-04-01 → 2023-09-30¥165.7bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥165.7bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥8.9bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥9.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2022-04-01 → 2022-09-30¥55.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2022-04-01 → 2022-09-30¥55.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2022-04-01 → 2022-09-30¥49.3bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2022-04-01 → 2022-09-30¥49.3bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.7bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2022-04-01 → 2022-09-30¥64.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2022-04-01 → 2022-09-30¥64.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2022-04-01 → 2022-09-30¥5.3bn
—segment totalrevenue2022-04-01 → 2022-09-30¥169.5bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥169.5bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥20.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 914
ItemContextValueUnit
Net cash provided by used in investing activities IFRSCurrentYTDDuration-2125000000JPY
Net increase decrease in short term borrowings fin cf IFRSPrior1YTDDuration-234000000JPY
Net increase decrease in short term borrowings fin cf IFRSCurrentYTDDuration11000000JPY
Proceeds from long term borrowings fin cf IFRSPrior1YTDDuration－JPY
Proceeds from long term borrowings fin cf IFRSCurrentYTDDuration62215000000JPY
Repayments of long term borrowings fin cf IFRSPrior1YTDDuration-12924000000JPY
Repayments of long term borrowings fin cf IFRSCurrentYTDDuration-75514000000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-2912000000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-2877000000JPY
Proceeds from issuance of shares fin cf IFRSPrior1YTDDuration182000000JPY
Proceeds from issuance of shares fin cf IFRSCurrentYTDDuration171000000JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSPrior1YTDDuration－JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSCurrentYTDDuration-2611000000JPY
Dividends paid to owners of parent fin cf IFRSPrior1YTDDuration-4704000000JPY
Dividends paid to owners of parent fin cf IFRSCurrentYTDDuration-4512000000JPY
Other fin cf IFRSPrior1YTDDuration4000000JPY
Other fin cf IFRSCurrentYTDDuration-496000000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-20589000000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration-23613000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration2041000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration3565000000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration-21519000000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration504000000JPY
Cash and cash equivalents IFRSPrior2YearInstant95232000000JPY
Cash and cash equivalents IFRSPrior1YearInstant60933000000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant73713000000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant61437000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember55401000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember64825000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember49295000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember169522000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember1062000000JPY
Revenue from external customers IFRSPrior1YTDDuration170584000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember55401000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember64825000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember49295000000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember169522000000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember1062000000JPY
Revenue IFRSPrior1YTDDuration170584000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember12013000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember5250000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember2719000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember19983000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-9442000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass